We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OND Backs Fabre-Kramer on Efficacy Review Appeal
Small drugmaker Fabre-Kramer Pharmaceuticals won a big victory Thursday after the FDA ignored its own internal advisory committee recommendations and negative determinations by the Office of New Drugs’ Office of Drug Evaluation I.